Novo Nordisk: acquires program from Prothena

(CercleFinance.com) - Novo Nordisk announces that it has entered into a definitive agreement with Prothena Corporation, under which Novo Nordisk acquires its clinical-stage antibody PRX004 and more broadly its program for the rare, progressive and fatal disease ATTR amyloidosis.


Under the terms of the agreement, the Danish healthcare group acquires full ownership of Prothena's subsidiary and all worldwide intellectual property and related rights to Prothena's ATTR amyloidosis business and pipeline.

Prothena is eligible to receive development and sales milestone payments of up to 1.2 billion dollars, including 100 million dollars in upfront and near-term clinical milestone payments.


Copyright (c) 2021 CercleFinance.com. All rights reserved.